Menu
SOUTH SAN FRANCISCO, CA, Feb. 26, 2020 - Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with SOPHiA GENETICS, leader in Data-Driven Medicine to bring access to the universal SOPHiA Platform for advanced genomic analysis to Twist’s customers, providing the analysis and interpretation of sequencing information. Together, the technologies will allow a customer to go from sample to interpretation of the results quickly and efficiently.
Sequencing the whole genome is expensive and often does not provide the depth of information needed for individual genes and the role they play in complex diseases. Target enrichment enables genomic sequencing efforts to be focused in specific regions of interest, which reduces cost and analysis time. Genomic solutions that combine Twist NGS enrichment solutions along with the SOPHiA AI-powered Platform for advanced DNA analysis are designed to support the implementation of NGS application for somatic and germline testing.
“SOPHiA’s mission is to democratize access to Data-Driven Medicine all around the world.With the addition of SOPHiA’s technology to Twist’s advanced products, clinical researchers will benefit from end-to-end, highly-accurate and reliable genomic solutions,” commented Jurgi Camblong CEO and Co-founder of SOPHiA GENETICS. “The combined solution will ultimately help experts precisely detect and characterize genomic mutations and use that information to improve outcomes.”
“Genomics research is enabling a shift from broad-based “one-size-fits-all” approach to a personalized experience,” commented Emily M. Leproust, Ph.D., CEO and co-founder of Twist. “Pairing our industry-leading, rapidly customizable enrichment efficiency with SOPHiA’s robust analytical platform provides customers an important solution to achieve clinically actionable data while saving on sequencing costs. We are excited to work with SOPHiA to provide this new combined offering to clinical researchers around the world.”
For more information, please visit www.twistbioscience.com and www.SOPHiAGENETICS.com.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
